This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Journalology/ Peer Review/ Authorship  • Dermatology  • Randomized Controlled Trial  • Dermatology, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

A Statement From the International Committee of Medical Journal Editors

Arch Dermatol. 2005;141:76-77.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Altruism and trust lie at the heart of research on human subjects. Altruistic individuals volunteer for research because they trust that their participation will contribute to improved health for others and that researchers will minimize risks to participants. In return for the altruism and trust that make clinical research possible, the research enterprise has an obligation to conduct research ethically and to report it honestly. Honest reporting begins with revealing the existence of all clinical studies, even those that reflect unfavorably on a research sponsor’s product.

Unfortunately, selective reporting of trials does occur, and it distorts the body of evidence available for clinical decision-making. Researchers (and journal editors) are generally most enthusiastic about the publication of trials that show either a large effect of a new treatment (positive trials) or equivalence of 2 approaches to treatment (noninferiority trials). Researchers (and journals) typically are less excited about trials that show that . . . [Full Text of this Article]

AUTHOR INFORMATION
Catherine D. DeAngelis, MD, MPH; Jeffrey M. Drazen, MD; Frank A. Frizelle, MBChB, MMedSc, FRACS; Charlotte Haug, MD, PhD, MSc; John Hoey, MD; Richard Horton, FRCP; Sheldon Kotzin, MLS; Christine Laine, MD, MPH; Ana Marusic, MD, PhD; A. John P. M. Overbeke, MD, PhD; Torben V. Schroeder, MD, DMSc; Hal C. Sox, MD; Martin B. Van Der Weyden, MD
Author Affiliations: Dr DeAngelis is editor-in-chief, JAMA; Dr Drazen is editor-in-chief, New England Journal of Medicine; Prof Frizelle is editor, The New Zealand Medical Journal; Dr Haug is editor-in-chief, Norwegian Medical Journal; Dr Hoey is editor, CMAJ; Dr Horton is editor, The Lancet; Mr Kotzin is executive editor, MEDLINE; Dr Laine is senior deputy editor, Annals of Internal Medicine; Dr Marusic is editor, Croatian Medical Journal; Dr Overbeke is executive editor, Nederlands Tijdschrift voor Geneeskunde (Dutch Journal of Medicine); Dr Schroeder is editor, Journal of the Danish Medical Association; Dr Sox is editor, Annals of Internal Medicine; and Dr Van Der Weyden is editor, The Medical Journal of Australia.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Clinical Trial Registration: A Step Forward in Providing Transparency for the Positive and Negative Results of Clinical Trials
Jeffrey P. Callen and June Robinson
Arch Dermatol. 2005;141(1):75.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Bidirectional Conflicts of Interest Involving Industry and Medical Journals: Who Will Champion Integrity?
Lanier
Mayo Clin Proc. 2009;84:771-775.
FULL TEXT